Cysteinyl‐leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends
Abstract Cysteinyl‐leukotrienes (cysteinyl‐LTs), that is, LTC4, LTD4, and LTE4, trigger
contractile and inflammatory responses through the specific interaction with G protein …
contractile and inflammatory responses through the specific interaction with G protein …
Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I
M Sokolowska, GE Rovati, Z Diamant, E Untersmayr… - Allergy, 2021 - Wiley Online Library
Eicosanoids are biologically active lipid mediators, comprising prostaglandins, leukotrienes,
thromboxanes, and lipoxins, involved in several pathophysiological processes relevant to …
thromboxanes, and lipoxins, involved in several pathophysiological processes relevant to …
Influence of leukotriene pathway polymorphisms on response to montelukast in asthma
JJ Lima, S Zhang, A Grant, L Shao… - American journal of …, 2006 - atsjournals.org
Rationale: Interpatient variability in montelukast response may be related to variation in
leukotriene pathway candidate genes. Objective: To determine associations between …
leukotriene pathway candidate genes. Objective: To determine associations between …
Leukotriene pathway genetics and pharmacogenetics in allergy
Leukotrienes (LT) are biologically active lipid mediators known to be involved in allergic
inflammation. Leukotrienes have been shown to mediate diverse features of allergic …
inflammation. Leukotrienes have been shown to mediate diverse features of allergic …
Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial
Background The effectiveness of intermittent montelukast for wheeze in young children is
unclear. We aimed to assess whether intermittent montelukast is better than placebo for …
unclear. We aimed to assess whether intermittent montelukast is better than placebo for …
Advanced phenotyping in hypersensitivity drug reactions to NSAID s
P Ayuso, N Blanca‐López, I Doña… - Clinical & …, 2013 - Wiley Online Library
Non‐steroidal anti‐inflammatory drugs (NSAID s) are the medications most frequently
involved in hypersensitivity drug reactions. Because NSAID s are prescribed for many …
involved in hypersensitivity drug reactions. Because NSAID s are prescribed for many …
[HTML][HTML] ALOX5 promoter genotype and response to montelukast in moderate persistent asthma
BACKGROUND: It was hypothesized that asthmatic patients with mutant alleles in the
leukotriene pathway should not respond to leukotriene receptor antagonists and the concept …
leukotriene pathway should not respond to leukotriene receptor antagonists and the concept …
ALOX5 promoter genotype, asthma severity and LTC4 production by eosinophils
Background: The number of Sp1–Egr1 binding tandem repeats at the ALOX5 promoter
influences gene transcription and may modify the response to anti‐leukotriene treatment …
influences gene transcription and may modify the response to anti‐leukotriene treatment …
Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk
JE Goodman, ED Bowman, SJ Chanock… - …, 2004 - academic.oup.com
In the human colon, arachidonic acid is metabolized primarily by cyclooxygenase (COX) and
arachidonate lipoxygenase (ALOX) to bioactive lipids, which are implicated in colon cancer …
arachidonate lipoxygenase (ALOX) to bioactive lipids, which are implicated in colon cancer …
Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia
SE Kleinstein, L Heath, KW Makar… - Genes …, 2013 - Wiley Online Library
Arachidonate lipoxygenase (ALOX) enzymes metabolize arachidonic acid to generate
potent inflammatory mediators and play an important role in inflammation‐associated …
potent inflammatory mediators and play an important role in inflammation‐associated …